Plain-English translation of NCT07385417 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a newer procedure called FARAPULSE electroporation to treat atrial fibrillation (irregular heartbeat) in people who have both an irregular heartbeat and a type of heart weakness called HFpEF. About half of the 200 patients in the study will receive the electroporation procedure, while the other half will receive standard heart rhythm medications. The goal is to see if this newer approach works better and is safe for these patients.
Many patients with both irregular heartbeat and this type of heart weakness struggle with current medications alone. This trial exists to find out whether the newer electroporation procedure might offer a better treatment option for these patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either receive the electroporation procedure or take standard heart rhythm medications. If you are in the procedure group, you will undergo an ablation procedure where a thin tube is threaded to your heart to help restore normal rhythm. Both groups will have regular follow-up visits to monitor your heart rhythm and overall health. The study will track how well the treatment works and any side effects over time.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Germany